Hyderabad: Bharat Biotech, the Developer of Covid-19 Covaxin Vaccine, on Friday said it was over, with direct effects, Mou on November 24, 2020, with Brazilian partners for Covaxin – Precisa Medicamantos and Envixia Pharmaceuticals.
This step came a few days after Brazil suspended a $ 324 million contract to get 20 million doses of Covaxin.
While Bharat Biotech did not describe the reason to stop the MoU, said: “We have recently been told that certain letters, which are intended to be carried out by the company executive, are being circulated online.
We want to firmly state that these documents have not been issued by the company or executive and therefore loud deny the same thing.
“” The company also emphasizes that all its actions, including global transactions, are carried out in accordance with local law and that the company employs and follows the highest ethical, integrity, and compliance standards every time, ” He said in a statement issued late on Friday afternoon.
But the company, said it would continue to work with Brazilian Health Regulators Anvisa to complete the regulatory approval process for Covaxin.
Bharat Biotech also said he would pursue approval in various countries according to the legal requirements applicable in each country.
Indicates that it entered the MoU with Precisa and Envixia for the purpose of introducing innovative Covid-19 vaccines in the Brazilian region, Bharat Biotech said it had offered to supply Covaxin to Brazil as part of its global supply outreach.
“Global prices (Save for India) from Covaxin have been set between US $ 15-20.
Thus, Covaxin has been offered to the Brazilian government at a rate of US $ 15 per dose.
Furthermore, the company has not yet received payments in advance, also does not provide Vaccines for the Ministry of Health in Brazil, “he said.